Changes in company's own shares

By Alvotech | December 29, 2025, 2:40 PM

Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares.

Attachment

Alvotech Own Shares Notification 29 Dec 2025

Mentioned In This Article

Latest News

Feb-11	Alvotech Announces Increase in Number of Own Shares ALVO -6.73% GlobeNewswire
Feb-05	Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio ALVO GlobeNewswire
Feb-04	Alvotech (ALVO): A Bull Case Theory ALVO Insider Monkey
Feb-02	Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates ALVO GlobeNewswire
Jan-29	Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg ALVO GlobeNewswire
Jan-22	Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y ALVO Zacks
Jan-16	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? ALVO Zacks
Jan-09	Alvotech (ALVO) Secures $100 Million in New Financing ALVO Insider Monkey
Jan-07	Correction: Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
Jan-06	Transactions of Managers and Closely Associated Persons ALVO -6.53% GlobeNewswire
Jan-06	Alvotech announces planned CEO succession and leadership transition ALVO -6.53% GlobeNewswire
Dec-31	Alvotech Secures Term Loan Facility of USD 100 Million ALVO GlobeNewswire
Dec-29	Changes in company's own shares ALVO -5.51% GlobeNewswire
Dec-22	Alvotech's Financial Calendar for 2026 ALVO GlobeNewswire
Dec-22	Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma ALVO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.